Valuation: Sage Therapeutics, Inc.

Market Cap 544M 473M 440M 404M 763M 51.89B 774M 5.18B 2.03B 25.83B 2.04B 2B 86.62B P/E 2023
-2.39x
P/E 2024 -0.82x
Enterprise Value 50.98M 44.32M 41.25M 37.87M 71.52M 4.87B 72.63M 486M 191M 2.42B 191M 187M 8.12B EV / Sales 2023
6.4x
EV / Sales 2024 -3.89x
Free-Float
99.75%
Yield 2023 *
-
Yield 2024 -
3 years 4.62
Extreme 4.62
37.16
5 years 4.62
Extreme 4.62
59.99
10 years 4.62
Extreme 4.62
195.97
Manager TitleAgeSince
President 64 2025-07-30
General Counsel - 2020-07-31
Director TitleAgeSince
Director/Board Member 64 2025-07-30
Date Insider Type Main position Quantity % Market Cap.
7/31/25 Issuer sale

Director

21,500 0.0350%
7/31/25 Issuer sale

Chief Technology Officer

72,961 0.1187%
7/31/25 Tender

Director

43,499 0.0708%
Change 5-day change 1-year change 3-year change Capi.($)
-0.23%-.--%-.--%-74.97% 544M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.14%-3.41%+31.03%+134.12% 23.44B
Weighted average by Cap. +0.23%-2.95%+28.60%+119.53%

Financials

2023 2024
Net sales 86.46M 75.16M 69.95M 64.23M 121M 8.25B 123M 825M 324M 4.11B 325M 318M 13.78B 41.24M 35.85M 33.37M 30.64M 57.86M 3.94B 58.75M 393M 154M 1.96B 155M 151M 6.57B
Net income -541M -471M -438M -402M -760M -51.69B -771M -5.16B -2.03B -25.73B -2.03B -1.99B -86.29B -401M -348M -324M -298M -562M -38.25B -571M -3.82B -1.5B -19.04B -1.5B -1.47B -63.85B
Net Debt -748M -650M -605M -556M -1.05B -71.41B -1.07B -7.13B -2.8B -35.55B -2.81B -2.75B -119B -493M -428M -399M -366M -691M -47.02B -702M -4.7B -1.84B -23.41B -1.85B -1.81B -78.5B
Logo Sage Therapeutics, Inc.
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Employees
353
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SAGE Stock